| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Platelets | 79 | 2025 | 180 | 16.290 |
Why?
|
| Platelet Activation | 57 | 2024 | 89 | 11.150 |
Why?
|
| Platelet Aggregation Inhibitors | 39 | 2021 | 252 | 6.300 |
Why?
|
| Flow Cytometry | 33 | 2025 | 671 | 4.710 |
Why?
|
| Platelet Aggregation | 32 | 2022 | 59 | 4.220 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 11 | 2018 | 23 | 3.810 |
Why?
|
| Platelet Function Tests | 25 | 2024 | 35 | 3.690 |
Why?
|
| Ticlopidine | 19 | 2018 | 66 | 3.100 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 24 | 2021 | 50 | 2.990 |
Why?
|
| Piperazines | 13 | 2013 | 93 | 2.450 |
Why?
|
| Blood Platelet Disorders | 7 | 2024 | 11 | 2.410 |
Why?
|
| Receptors, Purinergic P2Y12 | 12 | 2018 | 16 | 2.280 |
Why?
|
| Aspirin | 16 | 2018 | 186 | 2.260 |
Why?
|
| P-Selectin | 20 | 2021 | 26 | 2.230 |
Why?
|
| Thiophenes | 12 | 2018 | 43 | 2.090 |
Why?
|
| Dinucleoside Phosphates | 6 | 2018 | 38 | 2.060 |
Why?
|
| Adenosine Diphosphate | 18 | 2016 | 59 | 2.050 |
Why?
|
| Platelet-Rich Plasma | 6 | 2021 | 8 | 2.040 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 7 | 2024 | 8 | 2.040 |
Why?
|
| Hemostasis | 7 | 2024 | 27 | 1.900 |
Why?
|
| Receptors, Purinergic P2Y1 | 7 | 2018 | 8 | 1.790 |
Why?
|
| Platelet Count | 8 | 2021 | 33 | 1.640 |
Why?
|
| Anemia, Sickle Cell | 8 | 2021 | 66 | 1.630 |
Why?
|
| Receptor, PAR-1 | 4 | 2021 | 8 | 1.430 |
Why?
|
| Biomarkers | 18 | 2024 | 1210 | 1.420 |
Why?
|
| Purinergic P2 Receptor Antagonists | 5 | 2013 | 5 | 1.420 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 5 | 2018 | 21 | 1.370 |
Why?
|
| CD40 Ligand | 8 | 2023 | 163 | 1.290 |
Why?
|
| Humans | 122 | 2025 | 59517 | 1.210 |
Why?
|
| Serotonin | 3 | 2024 | 66 | 1.210 |
Why?
|
| Hemorrhage | 7 | 2021 | 277 | 1.210 |
Why?
|
| Blood Coagulation | 11 | 2022 | 50 | 1.050 |
Why?
|
| Sudden Infant Death | 2 | 2024 | 22 | 1.050 |
Why?
|
| Prasugrel Hydrochloride | 13 | 2017 | 26 | 1.040 |
Why?
|
| Cardiac Catheterization | 4 | 2021 | 250 | 1.020 |
Why?
|
| Thrombocytopenia | 5 | 2021 | 53 | 1.000 |
Why?
|
| Immunophenotyping | 6 | 2023 | 191 | 0.940 |
Why?
|
| 14-3-3 Proteins | 1 | 2024 | 19 | 0.920 |
Why?
|
| Drug Resistance | 5 | 2009 | 97 | 0.910 |
Why?
|
| Coronary Thrombosis | 4 | 2018 | 23 | 0.910 |
Why?
|
| Acute Coronary Syndrome | 6 | 2018 | 258 | 0.900 |
Why?
|
| Thrombasthenia | 6 | 2022 | 6 | 0.860 |
Why?
|
| Epidermal Growth Factor | 4 | 2021 | 52 | 0.850 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2019 | 158 | 0.840 |
Why?
|
| Immunoglobulin Fab Fragments | 8 | 2013 | 43 | 0.840 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 2 | 2013 | 6 | 0.830 |
Why?
|
| Megakaryocytes | 2 | 2022 | 20 | 0.810 |
Why?
|
| Coronary Artery Disease | 8 | 2016 | 277 | 0.810 |
Why?
|
| Integrin beta3 | 4 | 2018 | 9 | 0.800 |
Why?
|
| Antibodies, Monoclonal | 17 | 2013 | 873 | 0.780 |
Why?
|
| Cardiovascular Diseases | 8 | 2015 | 827 | 0.740 |
Why?
|
| Electricity | 3 | 2021 | 11 | 0.730 |
Why?
|
| Male | 55 | 2024 | 27572 | 0.710 |
Why?
|
| Female | 55 | 2024 | 30918 | 0.690 |
Why?
|
| Thromboxane B2 | 4 | 2017 | 21 | 0.680 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 53 | 0.670 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2021 | 169 | 0.670 |
Why?
|
| Leukocytes | 9 | 2025 | 108 | 0.650 |
Why?
|
| Thrombopoiesis | 1 | 2018 | 2 | 0.630 |
Why?
|
| Hematologic Agents | 1 | 2018 | 4 | 0.630 |
Why?
|
| Thiazoles | 1 | 2018 | 47 | 0.620 |
Why?
|
| Cyclooxygenase 1 | 2 | 2009 | 20 | 0.610 |
Why?
|
| Pyrazoles | 5 | 2019 | 74 | 0.600 |
Why?
|
| Dog Diseases | 1 | 2018 | 55 | 0.590 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2018 | 809 | 0.580 |
Why?
|
| Communication | 2 | 2022 | 554 | 0.580 |
Why?
|
| Platelet Membrane Glycoproteins | 13 | 2016 | 17 | 0.580 |
Why?
|
| Cell-Derived Microparticles | 4 | 2021 | 8 | 0.570 |
Why?
|
| Platelet Adhesiveness | 8 | 2016 | 13 | 0.570 |
Why?
|
| Liver Diseases | 1 | 2018 | 137 | 0.560 |
Why?
|
| Middle Aged | 40 | 2021 | 16276 | 0.560 |
Why?
|
| Adenosine | 2 | 2017 | 71 | 0.560 |
Why?
|
| Pulsed Radiofrequency Treatment | 1 | 2016 | 2 | 0.550 |
Why?
|
| Cardiology | 1 | 2018 | 165 | 0.540 |
Why?
|
| Double-Blind Method | 12 | 2019 | 680 | 0.530 |
Why?
|
| Cytoplasmic Granules | 3 | 2022 | 53 | 0.500 |
Why?
|
| Proton Pump Inhibitors | 2 | 2013 | 39 | 0.490 |
Why?
|
| Membrane Glycoproteins | 1 | 2018 | 669 | 0.480 |
Why?
|
| Adult | 32 | 2021 | 15787 | 0.470 |
Why?
|
| Case-Control Studies | 10 | 2018 | 1063 | 0.440 |
Why?
|
| Phenotype | 7 | 2023 | 1157 | 0.430 |
Why?
|
| Polymorphism, Genetic | 2 | 2017 | 197 | 0.430 |
Why?
|
| Platelet-Derived Growth Factor | 4 | 2021 | 19 | 0.410 |
Why?
|
| Microfilament Proteins | 6 | 2017 | 116 | 0.410 |
Why?
|
| Thrombin | 9 | 2021 | 34 | 0.410 |
Why?
|
| Omeprazole | 1 | 2012 | 5 | 0.400 |
Why?
|
| Peptides | 4 | 2013 | 549 | 0.400 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 7 | 2021 | 455 | 0.370 |
Why?
|
| Cell Adhesion Molecules | 5 | 2017 | 91 | 0.370 |
Why?
|
| Cross-Over Studies | 6 | 2017 | 149 | 0.360 |
Why?
|
| Receptors, Thrombin | 4 | 2022 | 4 | 0.360 |
Why?
|
| Wiskott-Aldrich Syndrome | 2 | 2023 | 3 | 0.350 |
Why?
|
| Phosphoproteins | 5 | 2017 | 216 | 0.350 |
Why?
|
| Purinergic P2 Receptor Agonists | 1 | 2009 | 1 | 0.340 |
Why?
|
| Thrombosis | 6 | 2024 | 195 | 0.330 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2019 | 674 | 0.320 |
Why?
|
| Fibrinogen | 7 | 2006 | 38 | 0.320 |
Why?
|
| Infant | 4 | 2024 | 1527 | 0.320 |
Why?
|
| Young Adult | 13 | 2021 | 4331 | 0.300 |
Why?
|
| Treatment Outcome | 11 | 2019 | 5183 | 0.300 |
Why?
|
| Clot Retraction | 1 | 2007 | 6 | 0.300 |
Why?
|
| Monocytes | 6 | 2015 | 351 | 0.300 |
Why?
|
| Blood Coagulation Factors | 1 | 2007 | 14 | 0.290 |
Why?
|
| Dogs | 7 | 2018 | 317 | 0.290 |
Why?
|
| Adolescent | 11 | 2021 | 5932 | 0.290 |
Why?
|
| Fibrinolytic Agents | 4 | 2016 | 165 | 0.290 |
Why?
|
| Cytochrome P-450 CYP2C19 | 4 | 2016 | 10 | 0.290 |
Why?
|
| Arachidonic Acid | 3 | 2006 | 39 | 0.290 |
Why?
|
| Prodrugs | 1 | 2007 | 32 | 0.280 |
Why?
|
| Factor Va | 2 | 2021 | 2 | 0.270 |
Why?
|
| Aged | 18 | 2019 | 13341 | 0.270 |
Why?
|
| Cyclooxygenase 2 | 1 | 2006 | 77 | 0.260 |
Why?
|
| Time Factors | 8 | 2018 | 3579 | 0.260 |
Why?
|
| Tyrosine | 2 | 2003 | 95 | 0.260 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 4 | 2013 | 12 | 0.260 |
Why?
|
| Drug Therapy, Combination | 4 | 2019 | 436 | 0.260 |
Why?
|
| Thrombelastography | 3 | 2018 | 6 | 0.260 |
Why?
|
| Electric Stimulation | 2 | 2015 | 139 | 0.240 |
Why?
|
| Kinetics | 4 | 2017 | 733 | 0.230 |
Why?
|
| Pain | 2 | 2021 | 406 | 0.230 |
Why?
|
| Hydrazines | 2 | 2015 | 12 | 0.230 |
Why?
|
| Benzoates | 2 | 2015 | 9 | 0.230 |
Why?
|
| Eczema | 1 | 2023 | 9 | 0.220 |
Why?
|
| Hypothermia, Induced | 1 | 2003 | 42 | 0.220 |
Why?
|
| Animals | 19 | 2022 | 19661 | 0.210 |
Why?
|
| Cell Proliferation | 3 | 2016 | 945 | 0.210 |
Why?
|
| Child, Preschool | 3 | 2018 | 1839 | 0.210 |
Why?
|
| Infant, Newborn | 4 | 2024 | 1311 | 0.210 |
Why?
|
| Diabetic Nephropathies | 3 | 2019 | 38 | 0.210 |
Why?
|
| Antibodies | 1 | 2023 | 177 | 0.200 |
Why?
|
| Area Under Curve | 2 | 2013 | 127 | 0.200 |
Why?
|
| Drug Interactions | 2 | 2013 | 115 | 0.200 |
Why?
|
| Annexin A5 | 2 | 2015 | 23 | 0.200 |
Why?
|
| NFATC Transcription Factors | 1 | 2022 | 21 | 0.200 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 282 | 0.200 |
Why?
|
| Collagen | 5 | 2009 | 121 | 0.200 |
Why?
|
| Healthy Volunteers | 2 | 2019 | 72 | 0.190 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2013 | 68 | 0.190 |
Why?
|
| Gaucher Disease | 1 | 2021 | 43 | 0.190 |
Why?
|
| Calgranulin A | 1 | 2021 | 5 | 0.190 |
Why?
|
| Cattle | 4 | 2019 | 308 | 0.190 |
Why?
|
| Calgranulin B | 1 | 2021 | 6 | 0.190 |
Why?
|
| Cell Line | 2 | 2016 | 2015 | 0.190 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 1551 | 0.190 |
Why?
|
| Coronary Restenosis | 1 | 2021 | 19 | 0.190 |
Why?
|
| Hemophilia A | 1 | 2021 | 57 | 0.180 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 2470 | 0.180 |
Why?
|
| Indicators and Reagents | 1 | 2021 | 44 | 0.180 |
Why?
|
| Neutrophils | 5 | 2022 | 357 | 0.180 |
Why?
|
| Peptide Fragments | 4 | 2015 | 353 | 0.180 |
Why?
|
| Predictive Value of Tests | 5 | 2015 | 1032 | 0.180 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 330 | 0.180 |
Why?
|
| Consensus | 1 | 2021 | 194 | 0.180 |
Why?
|
| Angioplasty, Balloon, Coronary | 6 | 2010 | 167 | 0.170 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2013 | 163 | 0.170 |
Why?
|
| Adenosine Monophosphate | 2 | 2017 | 26 | 0.170 |
Why?
|
| Hemoglobins | 1 | 2021 | 139 | 0.170 |
Why?
|
| Phosphatidylserines | 3 | 2021 | 17 | 0.170 |
Why?
|
| Endothelium, Vascular | 2 | 2016 | 174 | 0.160 |
Why?
|
| Drug Monitoring | 3 | 2021 | 99 | 0.160 |
Why?
|
| Child | 4 | 2018 | 4306 | 0.160 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2018 | 3 | 0.160 |
Why?
|
| Pyrimidines | 1 | 2019 | 122 | 0.160 |
Why?
|
| Pyrimidinones | 1 | 2018 | 15 | 0.160 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2018 | 26 | 0.160 |
Why?
|
| Reference Values | 2 | 2012 | 321 | 0.160 |
Why?
|
| Mean Platelet Volume | 2 | 2015 | 4 | 0.160 |
Why?
|
| Cell Differentiation | 2 | 2015 | 1295 | 0.160 |
Why?
|
| Platelet Membrane Glycoprotein IIb | 1 | 2018 | 1 | 0.160 |
Why?
|
| Electrochemical Techniques | 1 | 2018 | 16 | 0.160 |
Why?
|
| International Cooperation | 1 | 2018 | 82 | 0.150 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2018 | 138 | 0.150 |
Why?
|
| Blood Specimen Collection | 2 | 2016 | 19 | 0.150 |
Why?
|
| Calpain | 1 | 2017 | 7 | 0.150 |
Why?
|
| Sepsis | 1 | 2022 | 281 | 0.150 |
Why?
|
| Asphyxia | 1 | 2017 | 4 | 0.140 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2023 | 275 | 0.140 |
Why?
|
| Monitoring, Physiologic | 1 | 2018 | 150 | 0.140 |
Why?
|
| Gastroparesis | 1 | 2017 | 7 | 0.140 |
Why?
|
| Diabetic Neuropathies | 1 | 2017 | 9 | 0.140 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2018 | 197 | 0.140 |
Why?
|
| Calcium | 4 | 2021 | 556 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 201 | 0.140 |
Why?
|
| Light | 2 | 2015 | 202 | 0.140 |
Why?
|
| Genetic Variation | 2 | 2018 | 367 | 0.140 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2016 | 20 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2018 | 330 | 0.130 |
Why?
|
| Receptors, Purinergic P2X1 | 1 | 2015 | 1 | 0.130 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2015 | 12 | 0.130 |
Why?
|
| Purinergic P2X Receptor Antagonists | 1 | 2015 | 8 | 0.130 |
Why?
|
| Phosphorylation | 3 | 2013 | 861 | 0.130 |
Why?
|
| Myocardial Infarction | 3 | 2009 | 864 | 0.130 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2015 | 10 | 0.130 |
Why?
|
| Octoxynol | 1 | 2015 | 12 | 0.130 |
Why?
|
| Diabetic Angiopathies | 2 | 2016 | 25 | 0.120 |
Why?
|
| Factor V | 2 | 2008 | 5 | 0.120 |
Why?
|
| Anticoagulants | 2 | 2018 | 487 | 0.120 |
Why?
|
| Drug Stability | 1 | 2015 | 139 | 0.120 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 97 | 0.120 |
Why?
|
| Scattering, Radiation | 1 | 2015 | 72 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2018 | 735 | 0.120 |
Why?
|
| Cystic Fibrosis | 2 | 2007 | 110 | 0.120 |
Why?
|
| Wound Healing | 1 | 2016 | 177 | 0.120 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 120 | 0.120 |
Why?
|
| ROC Curve | 1 | 2015 | 259 | 0.120 |
Why?
|
| Coronary Angiography | 1 | 2015 | 172 | 0.120 |
Why?
|
| Hypoxia | 2 | 2017 | 110 | 0.120 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 136 | 0.120 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 376 | 0.120 |
Why?
|
| Signal Transduction | 3 | 2017 | 2891 | 0.120 |
Why?
|
| Risk Factors | 4 | 2018 | 5016 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2010 | 607 | 0.120 |
Why?
|
| Genotype | 5 | 2017 | 642 | 0.120 |
Why?
|
| Vascular Patency | 3 | 2009 | 134 | 0.120 |
Why?
|
| Stereoisomerism | 1 | 2014 | 68 | 0.110 |
Why?
|
| Hypertension | 1 | 2019 | 601 | 0.110 |
Why?
|
| Coronary Disease | 3 | 2005 | 250 | 0.110 |
Why?
|
| Cell Separation | 2 | 2005 | 149 | 0.110 |
Why?
|
| Odds Ratio | 1 | 2015 | 773 | 0.110 |
Why?
|
| Prospective Studies | 5 | 2014 | 3101 | 0.110 |
Why?
|
| Myeloproliferative Disorders | 1 | 2013 | 16 | 0.110 |
Why?
|
| Image Cytometry | 2 | 2025 | 4 | 0.110 |
Why?
|
| Chest Pain | 1 | 2014 | 85 | 0.110 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2013 | 16 | 0.110 |
Why?
|
| Aryldialkylphosphatase | 1 | 2013 | 19 | 0.100 |
Why?
|
| Drug Substitution | 1 | 2012 | 42 | 0.100 |
Why?
|
| Epithelial Cells | 1 | 2015 | 375 | 0.100 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 47 | 0.100 |
Why?
|
| Cell Adhesion | 2 | 2003 | 211 | 0.100 |
Why?
|
| Inflammation | 5 | 2022 | 1102 | 0.100 |
Why?
|
| Lansoprazole | 1 | 2012 | 1 | 0.100 |
Why?
|
| Dexlansoprazole | 1 | 2012 | 1 | 0.100 |
Why?
|
| Esomeprazole | 1 | 2012 | 2 | 0.100 |
Why?
|
| Comorbidity | 1 | 2015 | 1091 | 0.100 |
Why?
|
| Gene Expression | 1 | 2015 | 810 | 0.100 |
Why?
|
| Rats | 1 | 2015 | 1913 | 0.100 |
Why?
|
| Disease Models, Animal | 6 | 2022 | 2069 | 0.100 |
Why?
|
| Platelet Activating Factor | 1 | 2011 | 4 | 0.100 |
Why?
|
| Confidence Intervals | 1 | 2012 | 256 | 0.090 |
Why?
|
| Platelet Transfusion | 1 | 2011 | 13 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 277 | 0.090 |
Why?
|
| Thromboxane A2 | 2 | 2008 | 7 | 0.090 |
Why?
|
| Heterozygote | 2 | 2011 | 168 | 0.090 |
Why?
|
| Thromboplastin | 2 | 2007 | 8 | 0.090 |
Why?
|
| Withholding Treatment | 1 | 2010 | 39 | 0.090 |
Why?
|
| Hydroxyurea | 2 | 2021 | 24 | 0.090 |
Why?
|
| Patient Compliance | 1 | 2013 | 372 | 0.090 |
Why?
|
| In Vitro Techniques | 3 | 2011 | 475 | 0.090 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2011 | 53 | 0.090 |
Why?
|
| Receptors, Purinergic P2X | 1 | 2009 | 2 | 0.090 |
Why?
|
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2009 | 3 | 0.090 |
Why?
|
| Serotonin Antagonists | 1 | 2009 | 31 | 0.080 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2007 | 77 | 0.080 |
Why?
|
| Benzamides | 1 | 2009 | 51 | 0.080 |
Why?
|
| Morpholines | 1 | 2009 | 86 | 0.080 |
Why?
|
| Epitopes | 3 | 1992 | 298 | 0.080 |
Why?
|
| Protein Binding | 3 | 2002 | 1551 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 387 | 0.080 |
Why?
|
| Receptors, Peptide | 1 | 1988 | 32 | 0.080 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2008 | 43 | 0.080 |
Why?
|
| Cell Aggregation | 2 | 2025 | 23 | 0.080 |
Why?
|
| Recurrence | 2 | 2009 | 578 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 1 | 2010 | 193 | 0.070 |
Why?
|
| Biotransformation | 1 | 2007 | 20 | 0.070 |
Why?
|
| Circadian Rhythm | 1 | 2011 | 370 | 0.070 |
Why?
|
| Smoking | 1 | 2013 | 830 | 0.070 |
Why?
|
| Receptors, Adenosine A2 | 1 | 2007 | 5 | 0.070 |
Why?
|
| Receptors, Immunologic | 1 | 1988 | 178 | 0.070 |
Why?
|
| Blood Cells | 1 | 2007 | 18 | 0.070 |
Why?
|
| Oligopeptides | 4 | 1993 | 134 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2008 | 238 | 0.070 |
Why?
|
| Laboratories | 1 | 2007 | 27 | 0.070 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2006 | 23 | 0.070 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2006 | 27 | 0.070 |
Why?
|
| Thrombolytic Therapy | 1 | 2007 | 181 | 0.070 |
Why?
|
| Bayes Theorem | 1 | 2006 | 108 | 0.070 |
Why?
|
| Treatment Refusal | 1 | 2006 | 60 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2014 | 1023 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2007 | 364 | 0.070 |
Why?
|
| Models, Cardiovascular | 1 | 2006 | 76 | 0.060 |
Why?
|
| Endothelium | 2 | 2003 | 20 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 1095 | 0.060 |
Why?
|
| United States | 1 | 2018 | 7513 | 0.060 |
Why?
|
| Dalteparin | 2 | 2003 | 5 | 0.060 |
Why?
|
| Cell Communication | 2 | 2022 | 129 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2007 | 2104 | 0.060 |
Why?
|
| Tissue Fixation | 2 | 2001 | 23 | 0.060 |
Why?
|
| Heparin | 2 | 2003 | 113 | 0.060 |
Why?
|
| Erythrocytes | 1 | 2025 | 155 | 0.060 |
Why?
|
| Wiskott-Aldrich Syndrome Protein | 1 | 2023 | 7 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 926 | 0.060 |
Why?
|
| Crotalid Venoms | 2 | 1993 | 2 | 0.050 |
Why?
|
| Protein Conformation | 2 | 2001 | 766 | 0.050 |
Why?
|
| Binding, Competitive | 2 | 2001 | 102 | 0.050 |
Why?
|
| Obesity | 1 | 2011 | 1186 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2019 | 919 | 0.050 |
Why?
|
| Angina, Unstable | 1 | 2003 | 58 | 0.050 |
Why?
|
| Hemostatics | 1 | 2003 | 27 | 0.050 |
Why?
|
| Pharmacogenetics | 2 | 2012 | 23 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 115 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2002 | 133 | 0.050 |
Why?
|
| Venous Thrombosis | 1 | 2003 | 107 | 0.050 |
Why?
|
| Hirudins | 1 | 2001 | 10 | 0.050 |
Why?
|
| Integrins | 2 | 1993 | 108 | 0.050 |
Why?
|
| Epinephrine | 3 | 2008 | 45 | 0.050 |
Why?
|
| Extracellular Traps | 1 | 2022 | 40 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 1449 | 0.050 |
Why?
|
| Cell Division | 1 | 2003 | 443 | 0.050 |
Why?
|
| Antisickling Agents | 1 | 2021 | 6 | 0.050 |
Why?
|
| Blood Cell Count | 1 | 2021 | 33 | 0.050 |
Why?
|
| Factor VIII | 1 | 2021 | 32 | 0.050 |
Why?
|
| Actigraphy | 1 | 2021 | 47 | 0.040 |
Why?
|
| Microscopy, Confocal | 1 | 2001 | 220 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2001 | 344 | 0.040 |
Why?
|
| Mice | 3 | 2022 | 10280 | 0.040 |
Why?
|
| Guanylyl Cyclase C Agonists | 1 | 2019 | 1 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 119 | 0.040 |
Why?
|
| Amino Acid Sequence | 6 | 1992 | 1582 | 0.040 |
Why?
|
| Molecular Sequence Data | 6 | 1992 | 1979 | 0.040 |
Why?
|
| E-Selectin | 1 | 2018 | 19 | 0.040 |
Why?
|
| Placebos | 1 | 2018 | 72 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 2329 | 0.040 |
Why?
|
| Coronary Circulation | 2 | 2009 | 52 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 212 | 0.040 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 2017 | 12 | 0.040 |
Why?
|
| Paresis | 1 | 2017 | 16 | 0.040 |
Why?
|
| Autopsy | 1 | 2017 | 47 | 0.040 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2017 | 24 | 0.040 |
Why?
|
| Brain Stem | 1 | 2017 | 30 | 0.040 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2001 | 67 | 0.040 |
Why?
|
| Dosage Forms | 1 | 2017 | 3 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1225 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2017 | 198 | 0.030 |
Why?
|
| Edetic Acid | 2 | 2004 | 23 | 0.030 |
Why?
|
| Binding Sites | 4 | 1993 | 875 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2023 | 735 | 0.030 |
Why?
|
| Fibrin | 1 | 2016 | 20 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 133 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 39 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2016 | 111 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2016 | 133 | 0.030 |
Why?
|
| Biological Availability | 1 | 2017 | 189 | 0.030 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2015 | 7 | 0.030 |
Why?
|
| Insulin | 1 | 2019 | 687 | 0.030 |
Why?
|
| Heredity | 1 | 2015 | 7 | 0.030 |
Why?
|
| Exocytosis | 1 | 2015 | 60 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2012 | 669 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2016 | 177 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2013 | 500 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2016 | 120 | 0.030 |
Why?
|
| Alleles | 2 | 2013 | 424 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2016 | 570 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2007 | 202 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 1915 | 0.030 |
Why?
|
| Carotid Artery Thrombosis | 1 | 1993 | 7 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2014 | 162 | 0.030 |
Why?
|
| Temperature | 2 | 2011 | 301 | 0.030 |
Why?
|
| Feeder Cells | 1 | 2013 | 2 | 0.030 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2013 | 4 | 0.030 |
Why?
|
| Janus Kinase 2 | 1 | 2013 | 13 | 0.030 |
Why?
|
| Erythroid Cells | 1 | 2013 | 10 | 0.030 |
Why?
|
| Carbazoles | 1 | 2013 | 14 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2013 | 95 | 0.030 |
Why?
|
| Ligands | 2 | 1991 | 422 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 131 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2017 | 1989 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 253 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2013 | 179 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2012 | 23 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2013 | 250 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2012 | 34 | 0.020 |
Why?
|
| Cell Shape | 1 | 2011 | 13 | 0.020 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2013 | 135 | 0.020 |
Why?
|
| Body Temperature | 1 | 2011 | 44 | 0.020 |
Why?
|
| Homozygote | 1 | 2011 | 117 | 0.020 |
Why?
|
| Fibronectins | 1 | 1991 | 43 | 0.020 |
Why?
|
| Behavior | 1 | 2011 | 38 | 0.020 |
Why?
|
| Bleeding Time | 1 | 2011 | 6 | 0.020 |
Why?
|
| Chymotrypsin | 1 | 1991 | 28 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 675 | 0.020 |
Why?
|
| Genome, Human | 1 | 2013 | 219 | 0.020 |
Why?
|
| Hematocrit | 1 | 2011 | 33 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 2442 | 0.020 |
Why?
|
| Fetal Blood | 1 | 2011 | 71 | 0.020 |
Why?
|
| Cardiovascular System | 1 | 2011 | 42 | 0.020 |
Why?
|
| Polysomnography | 1 | 2011 | 54 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 208 | 0.020 |
Why?
|
| Models, Biological | 1 | 2016 | 1142 | 0.020 |
Why?
|
| Blood Coagulation Disorders | 1 | 1990 | 21 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 3195 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 403 | 0.020 |
Why?
|
| Denmark | 1 | 2010 | 22 | 0.020 |
Why?
|
| Drug Inverse Agonism | 1 | 2009 | 2 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2010 | 34 | 0.020 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2009 | 12 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 454 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2010 | 96 | 0.020 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2008 | 7 | 0.020 |
Why?
|
| Cations, Divalent | 1 | 1988 | 22 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2011 | 522 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 1572 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2005 | 595 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2009 | 236 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1039 | 0.020 |
Why?
|
| Phenethylamines | 1 | 2007 | 10 | 0.020 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2008 | 143 | 0.020 |
Why?
|
| Kidney | 1 | 2010 | 395 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 791 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2011 | 443 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2011 | 886 | 0.020 |
Why?
|
| Cell Membrane | 2 | 2005 | 492 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 355 | 0.020 |
Why?
|
| Species Specificity | 1 | 2007 | 337 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2006 | 70 | 0.020 |
Why?
|
| Random Allocation | 1 | 2006 | 199 | 0.020 |
Why?
|
| Factor Xa | 1 | 2005 | 7 | 0.020 |
Why?
|
| CD11b Antigen | 1 | 2005 | 22 | 0.020 |
Why?
|
| Macrophage-1 Antigen | 1 | 2005 | 31 | 0.020 |
Why?
|
| Coronary Vessels | 1 | 2006 | 110 | 0.020 |
Why?
|
| Disease Progression | 1 | 2010 | 1044 | 0.020 |
Why?
|
| Alprostadil | 1 | 2005 | 7 | 0.020 |
Why?
|
| Adenylyl Cyclases | 1 | 2005 | 21 | 0.020 |
Why?
|
| Ibuprofen | 1 | 2005 | 19 | 0.020 |
Why?
|
| Destrin | 1 | 2004 | 1 | 0.010 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2004 | 13 | 0.010 |
Why?
|
| Cytochalasin D | 1 | 2004 | 20 | 0.010 |
Why?
|
| Vitamin E | 1 | 2005 | 55 | 0.010 |
Why?
|
| Actin Depolymerizing Factors | 1 | 2004 | 5 | 0.010 |
Why?
|
| Age Factors | 1 | 2008 | 1518 | 0.010 |
Why?
|
| Matrix Metalloproteinases | 1 | 2004 | 16 | 0.010 |
Why?
|
| Chelating Agents | 1 | 2004 | 47 | 0.010 |
Why?
|
| Syndrome | 1 | 2004 | 173 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2005 | 143 | 0.010 |
Why?
|
| Exercise | 1 | 2011 | 916 | 0.010 |
Why?
|
| Dipeptides | 1 | 2004 | 62 | 0.010 |
Why?
|
| Solubility | 1 | 2004 | 174 | 0.010 |
Why?
|
| Mutation | 1 | 1992 | 2441 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2005 | 194 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 526 | 0.010 |
Why?
|
| Protease Inhibitors | 1 | 2004 | 104 | 0.010 |
Why?
|
| Methods | 1 | 2003 | 39 | 0.010 |
Why?
|
| Blood | 1 | 2003 | 28 | 0.010 |
Why?
|
| Acute Disease | 1 | 2005 | 659 | 0.010 |
Why?
|
| Saphenous Vein | 1 | 2003 | 43 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 170 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 5089 | 0.010 |
Why?
|
| Atherectomy | 1 | 2001 | 9 | 0.010 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2001 | 11 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 2001 | 42 | 0.010 |
Why?
|
| Specimen Handling | 1 | 2002 | 57 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 581 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2001 | 133 | 0.010 |
Why?
|
| Antibodies, Blocking | 1 | 2001 | 41 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 848 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2001 | 140 | 0.010 |
Why?
|
| Platelet Storage Pool Deficiency | 1 | 2000 | 1 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2002 | 194 | 0.010 |
Why?
|
| Blood Banks | 1 | 2000 | 9 | 0.010 |
Why?
|
| Calibration | 1 | 2000 | 65 | 0.010 |
Why?
|
| Quality Control | 1 | 2000 | 70 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 1992 | 694 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 1470 | 0.010 |
Why?
|
| Base Sequence | 2 | 1992 | 1313 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 2000 | 403 | 0.010 |
Why?
|
| DNA | 2 | 1992 | 794 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2000 | 842 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1993 | 219 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 1992 | 48 | 0.010 |
Why?
|
| CHO Cells | 1 | 1992 | 191 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1992 | 255 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 1992 | 195 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1991 | 183 | 0.010 |
Why?
|
| Hydrolysis | 1 | 1991 | 138 | 0.010 |
Why?
|
| Cricetinae | 1 | 1992 | 377 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 1993 | 397 | 0.010 |
Why?
|
| Amino Acids | 1 | 1992 | 141 | 0.010 |
Why?
|
| Primary Myelofibrosis | 1 | 1990 | 10 | 0.010 |
Why?
|
| Pancreas | 1 | 1991 | 147 | 0.010 |
Why?
|
| RNA | 1 | 1992 | 404 | 0.000 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1987 | 502 | 0.000 |
Why?
|